This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Thermo Fisher (TMO) End Market Growth Strong Despite Macro Woes
by Zacks Equity Research
Thermo Fisher's (TMO) electron microscopy, chromatography and mass spectrometry businesses are delivering strong growth in the academic and government end market.
QIAGEN (QGEN) Forges Alliance to Advance Microbiome Sciences
by Zacks Equity Research
QIAGEN (QGEN) announces a first-in-kind collaboration with Penn State University to help shape research, education and outreach in microbiomes.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business.
Universal Health (UHS) Up 5.3% in 6 Months: More Room to Run?
by Zacks Equity Research
Universal Health's (UHS) rising patient volumes and better pricing position the company well for growth.
Here's Why Insulet (PODD) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Alcon (ALC) Business Hurt by Macroeconomic Woes, Competition
by Zacks Equity Research
In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.
Thermo Fisher (TMO) End Markets Drive Growth Amid Macro Woes
by Zacks Equity Research
In the academic and government end markets, Thermo Fisher (TMO) is delivering strong growth in the electron microscopy, chromatography and mass spectrometry businesses.
Here's Why You Should Retain Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors remain optimistic about Edward Lifesciences (EW) due to the strength of its product group.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Medtronic's (MDT) expansion in global markets and stable solvency position.
Omnicell (OMCL) Gains From Innovation Amid Cost Pressure
by Zacks Equity Research
Omnicell (OMCL) plans to focus on integrating customer success functions into its broader organizational structure.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors remain optimistic about Teleflex (TFX), backed by the strong prospects of the Interventional business and stable solvency.
Boston Scientific (BSX) Initiates AVANT GUARD Clinical Trial
by Zacks Equity Research
Boston Scientific's (BSX) AVANT GUARD clinical trial is set to evaluate the FARAPULSE PFA System as the first-line treatment for persistent AF.
3 Reasons Why Growth Investors Shouldn't Overlook Insulet (PODD)
by Zacks Equity Research
Insulet (PODD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Globus Medical (GMED) Gains From Innovation Amid Macro Issues
by Zacks Equity Research
Globus Medical (GMED) is particularly seeing notable gains in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Walgreens (WBA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in U.S. Healthcare and International businesses is likely to drive Walgreens' (WBA) first-quarter 2024 performance.
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors remain optimistic about Labcorp (LH) due to impressive partnerships and expansion efforts in targeted high-growth areas.
5 Impressive MedTech Industry Growth Stocks to Buy for 2024
by Moumi Mondal
Stocks such as HAE, PEN, EXAS, PODD and CAH are set to garner remarkable growth for investors.
Here's Why You Should Invest in Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors are optimistic about Insulet (PODD), led by the strong adoption of Omnipod 5 and its strong solvency position.
Here's Why You Should Retain Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Illumina's (ILMN) strength in the genomics market and strong solvency position.
Ensign Group (ENSG) Rises 23% in 3 Months: More Room to Run?
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth, courtesy of an extensive treatment network, higher rental revenues and uninterrupted dividend hikes.
National Vision (EYE) Store Openings Aid, Macro Issues Stay
by Zacks Equity Research
In terms of store expansion, National Vision (EYE) continues to see sizable new opportunities for many years to come.
Bull of the Day: Insulet (PODD)
by David Bartosiak
A big earnings beat at the perfect time has this stock up over 50% in short order.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors remain optimistic about QIAGEN (QGEN), backed by strategic alliances and potential in the Molecular Diagnostics arena.